· Alteogen is developing ALT-P1, a long-acting human growth hormone, using its platform technology of NexP™. ALT-P1 is a flagship biobetter of Alteogen, which combines human growth hormone and NexP™.
· In pre-clinical trials, ALT-P1 not only showed greater efficacy in comparison with the first-generation human growth hormone, but also showed longer half-life. Also, safety of ALT-P1 was clearly proven in phase 1 clinical trial among healthy men. It is expected to show much lower toxicity and/or fewer side effects than other available or under development human growth hormones, due to lower therapeutic dosage requirement. Accordingly, it is reasonable to expect that ALT-P1 would be developed into the leading treatment regimen of its kind.
· Currently, phase IIa clinical trial for ALT-P1 is underway among adult patients with growth hormone deficiency. Phase II clinical trial among child patients with growth hormone deficiency will soon be held.